| Dr Lorene Brulez Dreisbach, DO | |
|
844 Washington Ave Ste 2700, Holland, MI 49423-7139 | |
| (616) 748-5785 | |
| Not Available |
| Full Name | Dr Lorene Brulez Dreisbach |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 7 Years |
| Location | 844 Washington Ave Ste 2700, Holland, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366962664 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 5101023014 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holland Community Hospital | Holland, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holland Community Hospital | 0446157291 | 142 |
News Archive
The way consumers use vapor and tobacco heating products can affect the levels of harmful and potentially harmful constituents they are exposed to, and a new study has analyzed how the use of these products compares with cigarette smoking.
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Despite previous studies hinting at tamoxifen's potential benefit for breast cancer survivors' heart health, California researchers have found that the breast cancer drug does not decrease survivors' risk of heart attack.
› Verified 4 days ago
| Entity Name | Holland Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780888099 PECOS PAC ID: 0446157291 Enrollment ID: O20031218000484 |
News Archive
The way consumers use vapor and tobacco heating products can affect the levels of harmful and potentially harmful constituents they are exposed to, and a new study has analyzed how the use of these products compares with cigarette smoking.
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Despite previous studies hinting at tamoxifen's potential benefit for breast cancer survivors' heart health, California researchers have found that the breast cancer drug does not decrease survivors' risk of heart attack.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lorene Brulez Dreisbach, DO 844 Washington Ave Ste 2700, Holland, MI 49423-7139 Ph: () - | Dr Lorene Brulez Dreisbach, DO 844 Washington Ave Ste 2700, Holland, MI 49423-7139 Ph: (616) 748-5785 |
News Archive
The way consumers use vapor and tobacco heating products can affect the levels of harmful and potentially harmful constituents they are exposed to, and a new study has analyzed how the use of these products compares with cigarette smoking.
Liquidia Technologies, a privately held nanotechnology company developing particle-based vaccines and therapeutics, today announced the initiation of human dosing of its lead vaccine product candidate, LIQ-001, in a Phase 1 clinical trial. LIQ-001, the first in a pipeline of PRINT® vaccines, is being developed as a seasonal influenza vaccine for enhanced protection in the elderly and represents the company's migration from proof of concept to the clinical application of PRINT technology.
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Despite previous studies hinting at tamoxifen's potential benefit for breast cancer survivors' heart health, California researchers have found that the breast cancer drug does not decrease survivors' risk of heart attack.
› Verified 4 days ago
Mark W Lenters, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 | |
James W Gerard, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 | |
Alysha Nicole Kirkwood, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 588 E Lakewood Blvd, 2nd Floor, Holland, MI 49424 Phone: 616-494-5850 Fax: 616-494-5901 | |
Dr. Michael Shawn Werkema, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 | |
Dr. Kristyn Dae Oswald, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 | |
Sarah E Strong, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 | |
Barbara E Puzycki, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 |